R&D pipeline progressing well
20/11/20 -"Better than expected performance of Tepezza and the upcoming launch of Amivantamab should bolster Genmab’s top line in the near term. Moreover, encouraging clinical data for pipeline assets, ..."
Pages
50
Language
English
Published on
20/11/20
You may also be interested by these reports :
30/07/26
Ipsen demonstrated robust performance in Q2, exceeding market expectations, which led to an upgraded 2026 guidance. While we may adjust our estimates ...
30/07/26
Bachem released its 1H26 results on 30 July 2026, delivering a strong operating performance for the half. Margins were affected by higher operating ...
29/07/26
The Q2 profitability was somewhat ahead of consensus, and the firm maintained its full-year guidance. Improving profitability and free cash flows, ...
28/07/26
The Q2 results were ahead of expectations, backed by strong growth across GSK’s key focus areas. The management maintained its full-year guidance. ...